KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) Shares Outstanding (Weighted Average) (2016 - 2025)

Cardlytics (CDLX) has disclosed Shares Outstanding (Weighted Average) for 10 consecutive years, with $53.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 9.83% year-over-year to $53.1 million, compared with a TTM value of $53.1 million through Dec 2025, up 9.83%, and an annual FY2025 reading of $53.1 million, up 9.83% over the prior year.
  • Shares Outstanding (Weighted Average) was $53.1 million for Q4 2025 at Cardlytics, up from $52.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $53.1 million in Q4 2025 and bottomed at $29.3 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $40.2 million, with a median of $35.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) fell 0.43% in 2023, then skyrocketed 40.64% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $32.2 million in 2021, then grew by 3.78% to $33.4 million in 2022, then grew by 9.18% to $36.5 million in 2023, then skyrocketed by 32.54% to $48.4 million in 2024, then rose by 9.83% to $53.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CDLX at $53.1 million in Q4 2025, $52.7 million in Q3 2025, and $52.8 million in Q2 2025.